About Paired box protein Pax-2
Paired box protein Pax-2 (PAX2) is a protein
from Homo sapiens identified by UniProt accession
Q02962, 417 residues long.
MolForge cross-references it against 0 known binders and
557 disease associations.
Target properties
| Protein name | Paired box protein Pax-2 |
| UniProt accession | Q02962 |
| Gene | PAX2 |
| Organism | Homo sapiens |
| Length | 417 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (557)
Diseases linked to this target (Open Targets).
- renal coloboma syndrome · score 0.84
- focal segmental glomerulosclerosis 7 · score 0.76
- focal segmental glomerulosclerosis · score 0.74
- neurodegenerative disease · score 0.49
- heart rate response to recovery post exercise · score 0.46
- systolic blood pressure · score 0.46
- heart rate response to exercise · score 0.42
- genetic disorder · score 0.41
- diastolic blood pressure · score 0.40
- familial idiopathic steroid-resistant nephrotic syndrome · score 0.39
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q02962-F1 | alphafold | PREDICTED | 60.93 | — |
Amino-acid sequence (417 residues)
MDMHCKADPF SAMHPGHGGV NQLGGVFVNG RPLPDVVRQR IVELAHQGVR PCDISRQLRV SHGCVSKILG RYYETGSIKP GVIGGSKPKV ATPKVVDKIA EYKRQNPTMF AWEIRDRLLA EGICDNDTVP SVSSINRIIR TKVQQPFHPT PDGAGTGVTA PGHTIVPSTA SPPVSSASND PVGSYSINGI LGIPRSNGEK RKRDEVEVYT DPAHIRGGGG LHLVWTLRDV SEGSVPNGDS QSGVDSLRKH LRADTFTQQQ LEALDRVFER PSYPDVFQAS EHIKSEQGNE YSLPALTPGL DEVKSSLSAS TNPELGSNVS GTQTYPVVTG RDMASTTLPG YPPHVPPTGQ GSYPTSTLAG MVPGSEFSGN PYSHPQYTAY NEAWRFSNPA LLSSPYYYSA APRGSAPAAA AAAYDRH
Explore Paired box protein Pax-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets